

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/22	A1	(11) International Publication Number: WO 95/09646 (43) International Publication Date: 13 April 1995 (13.04.95)
<p>(21) International Application Number: PCT/US94/10879</p> <p>(22) International Filing Date: 27 September 1994 (27.09.94)</p> <p>(30) Priority Data: 08/132,859 7 October 1993 (07.10.93) US 08/258,227 10 June 1994 (10.06.94) US</p> <p>(71) Applicant: THE GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER [US/US]; 2300 Eye Street, N.W., Washington, DC 20037 (US).</p> <p>(72) Inventors: GOLDSTEIN, Allan, L.; 6407 Bradley Boulevard, Bethesda, MD 20814 (US). FAGARASAN, Mirela, O.; Apartment 608 North, 950 25th Street, Washington, DC 20037 (US).</p> <p>(74) Agents: REPPER, George, R. et al.; Rothwell, Figg, Ernst & Kurz, 555 13th Street, N.W., #701 East, Washington, DC 20004 (US).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FL, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN β_4</p> <p>(57) Abstract</p> <p>A method of treating septic shock in a mammal including the administration of a septic shock-treating effective amount of Tβ_4 to the mammal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD OF TREATING SEPTIC SHOCK
USING THYMOSIN β_4

The present invention relates to a method of treating septic shock in mammals.

5 Description of Background Art

Thymosin β_4 ("T β_4 ") is a peptide which has been reported as containing 43 amino acids. Amino acid sequence information on T β_4 is disclosed in U.S. Patent No. 4,297,276, herein incorporated by reference.

10 T β_4 has been found to be present in numerous tissue types in mammals and has also been implicated in a wide variety of cellular and physiological processes including inducing terminal deoxynucleotidyl transferase activity of bone marrow cells, stimulating
15 secretion of hypothalamic luteinizing hormone releasing hormone and luteinizing hormone, inhibiting migration and enhancing antigen presentation of macrophages, and inducing phenotypic changes in T-cell lines in vitro.

 Septic shock is a condition in which infection is
20 widely disseminated in many areas of the body, the infection generally being disseminated through the blood from one tissue to another and causing extensive damage. Septic shock can occur with numerous medical conditions, including (1) peritonitis caused by the
25 spread of infection from the uterus and fallopian tubes; (2) peritonitis resulting from rupture of the gut, sometimes caused by intestinal disease or wounds; (3) generalized infection resulting from spread of a

simple infection; (4) generalized gangrenous infection resulting specifically from gas gangrene bacilli; and (5) infection spreading into the blood from the kidney or urinary tract. Septic shock is of critical concern from a clinical viewpoint because, among other reasons, this condition frequently leads to death.

Although septic shock is a somewhat common clinical phenomenon, the mechanisms involved as well as the pathological changes remain poorly understood. For example, despite the treatment of bacterial infection, many patients deteriorate further, which may be due to clinical sequelae of hypotension with low systemic vascular resistance, renal insufficiency, adult respiratory distress syndrome, severe coagulopathy and severe metabolic dysfunctions. Thus, there is an urgent need in the art for effective methods of treating septic shock.

Summary of the Invention

In accordance with the present invention, a method of treating septic shock in mammals includes administering a septic shock-treating effective amount of $T\beta_4$ to said mammals.

Description of the Preferred Embodiments

The terms "Thymosin β_4 ," and " $T\beta_4$," refer to peptides having the amino acid sequence disclosed in U.S. Patent No. 4,297,276, supra.

Mammalian septic shock occurs in association with a series of events in the mammal's body referred to as the "sepsis cascade". The sepsis cascade typically begins with bacterial infection of the mammalian host resulting in release of bacterial toxins, introduction of endotoxin, activation of host defense systems, i.e., plasma protein systems as well as cellular defense systems including endothelial cells,

macrophages, monocytes and neutrophils, with release of proinflammatory mediators including cytokines, lipid metabolites, proteases, toxic oxygen products, nitric oxide and adhesion proteins.

5 According to one aspect of the present invention, effective amounts of $T\beta_4$ are administered to a subject to reduce blood free radical levels in the subject, and thereby treat or prevent septic shock in the subject or obstruct progression of sepsis cascade in the subject.
10 $T\beta_4$ has been found to reduce blood free radical levels almost as much as SOD (super oxide dismutase), an enzyme that eliminates free radicals. When a septic shock-treating or a septic shock-preventing effective amount of $T\beta_4$ is administered to a mammal, the blood
15 levels of pathological mediators of bacteria-induced lethality are decreased in the mammal.

$T\beta_4$ has been found to obstruct the sepsis cascade in mammals. During sepsis, peroxidation of lipids in blood is increased (mMol of malonyldialdehyde), but
20 returned to normal or about normal with $T\beta_4$ administration. Sepsis also reduces circulating blood levels of glutathione. However, administration of $T\beta_4$ returns circulatory glutathione levels to normal or about normal.

25 As noted above, administration of $T\beta_4$ during sepsis decreases blood hydroperoxide levels and blood glutathione levels. Administration of $T\beta_4$ during sepsis also decreases cerebellar cGMP levels, and decreases the blood levels of arachidonic acid metabolites such
30 as $Tx\beta_2$ and 6-keto-PGF $_{1\alpha}$, PAF, and cytokines such as IL- 1α and TNF- α .

 While not wishing to be bound to any particular theory, it is believed that reducing blood levels of pathological mediators of bacteria-induced lethality in

a mammal decreases the amount of infection in the mammal which, in turn, aids in obstructing the sepsis cascade, and in preventing and treating septic shock.

Thus, according to the present invention, methods
5 of treating and preventing septic shock in mammals are provided. The methods of the present invention include administration of septic shock-treating effective amounts, septic shock-preventing effective amounts and sepsis cascade progression-obstructing effective
10 amounts of $T\beta_4$ to mammals.

According to preferred embodiments of the present invention, effective amounts of $T\beta_4$ are administered to subjects to treat or prevent septic shock in the subjects, or obstruct progression of sepsis cascade in
15 the subjects. In these embodiments, the subjects preferably are human.

According to preferred embodiments of the present invention, compositions containing $T\beta_4$ may be formulated in a conventional manner for administration by any
20 suitable route. Suitable routes of administration include, but are not limited to, oral, rectal, nasal, topical, vaginal, and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). Particularly preferred embodiments
25 utilize oral or parenteral administration, with parenteral administration being a more preferred embodiment. It will be appreciated that the preferred route may vary with the condition, age and species of the recipient.

30 While not essential, in preferred embodiments, $T\beta_4$ is administered as part of a pharmaceutical formulation. The formulations of the present invention comprise $T\beta_4$ together with one or more pharmaceutically acceptable carriers and optionally with other

therapeutic ingredients. The carrier(s) are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

5 The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may
10 conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and may be prepared by any suitable pharmaceutical methods.

Such methods include, but are not limited to, the step of bringing into association $T\beta_4$ with the carrier
15 which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association $T\beta_4$ with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

20 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of $T\beta_4$, as a powder or granules; as a solution or a suspension in an aqueous liquid or a
25 non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, etc.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a
30 suitable machine $T\beta_4$ in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered

compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.

5 Formulations suitable for topical administration include lozenges comprising $T\beta_4$ in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising $T\beta_4$ in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes
10 comprising $T\beta_4$ to be administered in a suitable liquid carrier.

 Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising $T\beta_4$ and a pharmaceutically
15 acceptable carrier, or may utilize a transdermal patch containing the ingredient to be administered.

 Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

20 Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size, for example, in the range from about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid
25 inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the
30 active ingredient.

 Formulations suitable for vaginal administration may be presented as tampons, creams, gels, pastes, foams or spray formulations containing, in addition to $T\beta_4$, suitable carriers.

SUBSTITUTE SHEET (RULE 26)

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may optionally contain anti-oxidants, buffers, bacteriostats and solutes which
5 render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example,
10 sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may
15 be prepared from sterile powders, granules and tablets of the kind previously described.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other
20 suitable agents having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.

A proposed dose for administration of the compositions in the present invention is a septic
25 shock-treating, septic shock-preventing or sepsis cascade progression-obstructing effective amount of $T\beta_4$, which can be in a range of from about 0.4 to about 4 mg of $T\beta_4$ per kg of body weight of recipient (mg/kg), preferably from about 1 to about 4 mg/kg. A dose can
30 be administered to the patient daily, one or more times per day of administration, e.g., two or three times per day, and doses can be administered one or more days per week, e.g., two, three, four, five, six or seven days per week.

SUBSTITUTE SHEET (RULE 26)

The invention is applicable to native (i.e., naturally occurring) $T\beta_4$ as well as synthetic $T\beta_4$ and recombinant $T\beta_4$ having the amino acid sequence of native $T\beta_4$, biologically active amino acid sequences
5 substantially similar thereto, or a biologically active abbreviated sequence form thereof, and their biologically active analogs (including muteins) having substituted, deleted, elongated, replaced, or otherwise modified sequences which possess bioactivity
10 substantially similar to that of native $T\beta_4$.

In accordance with one embodiment of the present invention, $T\beta_4$ can be administered in combination with a therapeutically effective amount of another substance useful in treating septic shock such as, for example,
15 antibiotics, or antibodies (polyclonal or monoclonal) directed to antigens located on endotoxins. Of course, the acceptable dosage range of the other substance will depend upon its properties (i.e., the acceptable dosage range will depend upon what other substance is being
20 administered).

$T\beta_4$ and another substance useful in treating septic shock can be administered "in combination" which, as defined herein, includes various schemes designed to administer $T\beta_4$ and the other substance to a subject,
25 whether or not the other substance and $T\beta_4$ are administered separately or together, such that the desired dosages of $T\beta_4$ and the other substance are present in the subject at the same time. Any suitable scheme can be used to administer $T\beta_4$ and another
30 substance useful in treating septic shock "in combination" in accordance with the present invention.

Suitable dosages of either $T\beta_4$ alone or $T\beta_4$ in combination with another substance useful in treating septic shock may be administered 1 to 6 times or more

per day. The precise dose administered will depend on the age, condition and other factors of the recipient.

The following examples are for illustrative purposes only, and are not to be construed in a limiting sense.

Example 1

Synthetic $T\beta_4$ was provided by Alpha 1 Biomedicals, Inc. (Two Democracy Center, 6903 Rockledge Drive, Ste. 1200, Bethesda, Maryland 20817). $T\beta_4$ was prepared by solid phase peptide synthesis.

Swiss-Webster mice 4-6 weeks of age (20 - 25g) were housed 6 per cage. The mice were divided into 2 groups: endotoxic mice (endotoxin 60 mg/kg i.p. in acute treatment) and endotoxic mice treated with $T\beta_4$, 5 minutes and 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post administration of the endotoxin. Survival was recorded 2 times a day for 7 days. The results are presented in Table I below. As can be seen, $T\beta_4$ protected against lethal endotoxin shock and increased the survival rate to as much as 100%.

Example 2

Swiss-Webster mice 4-6 weeks of age (20-25g) were divided into groups as follows.

1. Mice treated with a lethal dose of endotoxin (60 mg/kg).
2. Mice treated with 60 mg/kg endotoxin followed by an injection of 100 μ g $T\beta_4$ (5 minutes post administration of endotoxin).
3. Mice treated with 60 mg/kg endotoxin followed by 2 injections of 100 μ g/ $T\beta_4$ (immediately following and 2 hours post administration of endotoxin).
4. Mice treated with 60 mg/kg endotoxin followed by 3 injections of 100 μ g $T\beta_4$ (immediately following, 2 and 4 hours post administration of endotoxin).

The results presented in Tables I and II below indicate that $T\beta_4$, administered 3 times post administration of endotoxin, increased the survival rate of mice treated with endotoxin to 100%.

5

TABLE I

Experimental Groups

Survival of Swiss Webster Mice
Following Lethal Endotoxin
Dose and $T\beta_4$
(No. mice alive)

10

	0 hrs	24 hrs	48hrs	72hrs
Endotoxin 60 mg/kg	7	1	1	1
Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g 1x	7	4	3	3
15 Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g 2x	7	4	4	4
Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g 3x	7	7	7	7

TABLE II

20

Protective Effect of $T\beta_4$ on Survival of Mice Treated with
Lethal Doses of Endotoxin

EXPERIMENTAL GROUPS	Number of Mice Alive					
	0 hr.	24 hr.	48 hr.	72 hr.	7 day	14 day
Endotoxin 60 mg/kg	8	0				
30 Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g 3x	8	8	8	8	8	8

The results presented in Tables III - V below show effects of $T\beta_4$, respectively on mice cerebellar cGMP levels, blood serum TNF- α levels, and blood serum TNF- α and IL-1 α levels.

35

TABLE III

$T\beta_4$ effects on cGMP cerebellar levels in mice treated with lethal doses of endotoxin

5	EXPERIMENTAL GROUPS	Cerebellar cortex cyclic GMP (pmol per mg/protein)
	Control	10.1 \pm 0.2
10	Endotoxin 60 mg/kg i.p.	30.7 \pm 4.1
15	Endotoxin 60 mg/kg i.p. + $T\beta_4$ 0.8 mg/kg i.p.	12.1 \pm 0.9

TABLE IV

Serum TNF- α levels in mice treated with lethal doses of endotoxin

20	EXPERIMENTAL GROUPS	TNF- α (pg/ml)		
		1 hr	3 hr	5 hr
25	Endotoxin 60 mg/kg	1098 \pm 106	783 \pm 38	623 \pm 51
	Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g	823 \pm 79	535 \pm 47	480 \pm 45

TABLE V

Serum TNF- α and IL-1 α levels* in mice protected against endotoxin-induced lethality by pretreatment with SOD and $T\beta_4$

35	Pretreatment	TNF- α (pg/ml)	IL-1 α (pg/ml)
	None	4462 \pm 123	1137 \pm 123
	SOD (3.3 \times 10 ⁴ μ /kg)	63 \pm 5.1	53 \pm 3.1
40	$T\beta_4$ 100 μ g/mice	321 \pm 26.2	298 \pm 20

* Mice were pretreated with SOD (super oxide dismutase), 30 minutes before endotoxin administration. XX blood for determined of TNF α and IL-1 α levels was collected 1 hr after endotoxin administration.

Example 3

Using the same materials and methods as in examples 1 and 2, the time and dose-dependency of the protective effect of $T\beta_4$ on endotoxin lethality were studied. The results are presented in Tables II and III below.

As can be seen in Tables VI and VII, $T\beta_4$ had a protective effect on endotoxin toxicity when given immediately following, 2 and 4 hours after endotoxin treatment. The most effective protective dose was 100 μg $T\beta_4$ administered three times. Also, $T\beta_4$ partially increased the survival of mice treated with endotoxin when it was administered three times in doses of 50 μg and 20 μg $T\beta_4$. 10 μg $T\beta_4$ has also sometimes shown positive activity.

SUBSTITUTE SHEET (RULE 26)

TABLE VI

Survival of Swiss Webster Mice
Following Lethal Endotoxin
Dose and T β ₄
(No. mice alive)

Experimental Groups

5

	0 hrs	24 hrs	48 hrs	72 hrs	96 hrs	120 hrs
Endotoxin 60 mg/kg 8	4	4	4	4	4	4
Endotoxin 60 mg/kg 8 + T β ₄ 100 μ g, 3x; T β ₄ was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	8	8	8	8	8	8
Endotoxin 60 mg/kg 8 + T β ₄ 100 μ g, 3x; T β ₄ was admini- stered 2, 4 and 6 hrs. after endotoxin.	7	4	4	4	4	4
Endotoxin 60 mg/kg 8 + T β ₄ 10 μ g, 3x; T β ₄ was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	8	8	6	6	6	6

10

15

20

25

SUBSTITUTE SHEET (RULE 26)

TABLE VII

Experimental Groups Survival of Swiss Webster Mice
Following Lethal Endotoxin
Dose and T β ,
(No. mice alive)

		0 hrs	24 hrs	48 hrs	72 hrs	96 hrs	5 days	6 days
5	Endotoxin 60 mg/kg 10	4	3	3	3	3	3	3
10	Endotoxin 60 mg/kg 10 + T β , 50 μ g, 3x; i.p. T β , was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	9	7	7	7	7	7	7
15	Endotoxin 60 mg/kg 10 + T β , 20 μ g, 3x; i.p. T β , was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	5	4	4	3	3	3	3
20	Endotoxin 60 mg/kg 10 + T β , 10 μ g, 3x; i.p. T β , was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	3	3	3	3	3	3	3
25	Endotoxin 60 mg/kg 10 + T β , 10 μ g, 3x; i.p. T β , was admini- stered immediately following, 2 and 4 hrs. after endotoxin.	3	3	3	3	3	3	3

SUBSTITUTE SHEET (RULE 26)

Example 4

Using the same methods and materials as in examples 1-3, the effect which $T\beta_4$ has on blood levels of $IL-1\alpha$, $TNF-\alpha$, PAG , $Tx\beta_2$, and 6-keto- $PGF_1\alpha$, which are pathological mediators of endotoxin induced lethality, was studied. The results are presented in Tables IV-IX below.

As can be seen in Tables VIII-XIII, $T\beta_4$ decreased $IL-1\alpha$, $TNF-\alpha$ serum levels as well as PAF , $Tx\beta_2$, and 6-keto- $PGF_1\alpha$ plasma levels after administration of a lethal dose of endotoxin.

TABLE VIII

<u>EXPERIMENTAL GROUPS</u>		<u>IL-1α pg/ml (serum levels)</u>	
		<u>1 hr</u>	<u>3hr</u>
15	Endotoxin 60 mg/kg	492 \pm 45, 2	550 \pm 37, 1
	Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g administered simultaneously	147,5 \pm 15,1	207, 5 \pm 19,3

TABLE IX

<u>EXPERIMENTAL GROUPS</u>		<u>PAF (pg/ml) (plasma levels)</u>			
		<u>0.5 hr.</u>	<u>1 hr</u>	<u>2 hr</u>	<u>3 hr</u>
20	Endotoxin 60 mg/kg	78 \pm 6	279 \pm 17	127 \pm 13	55 \pm 3
25	Endotoxin 60 mg/kg + $T\beta_4$ 100 μ g administered simultaneously	63 \pm 7	161 \pm 17	66 \pm 5	46 \pm 5

TABLE X

<u>EXPERIMENTAL GROUPS</u>		<u>Txβ_2 (pg/ml) (plasma levels)</u>			
		<u>0.5 hr.</u>	<u>1 hr</u>	<u>2 hr</u>	<u>3 hr</u>
5	Endotoxin 60 mg/kg	1442 \pm 103	2937 \pm 258	912 \pm 105	695 \pm 65
10	Endotoxin 60 mg/kg + T β_4 100 μ g administered simultaneously	209 \pm 9,5	607 \pm 53	196 \pm 18	112 \pm 9

TABLE XI

<u>EXPERIMENTAL GROUPS</u>		<u>6-keto-PGF1α (pg/ml) (plasma levels)</u>			
		<u>0.5 hr.</u>	<u>1 hr</u>	<u>2 hr</u>	<u>3 hr</u>
15	Endotoxin 60 mg/kg	341 \pm 31	1141 \pm 112	897 \pm 75	811 \pm 7
20	Endotoxin 60 mg/kg + T β_4 100 μ g administered simultaneously	141 \pm 9	261 \pm 23	147 \pm 19	121 \pm 13

TABLE XII

<u>EXPERIMENTAL GROUPS</u>		<u>PAF (pg/ml) (serum levels)</u>		
		<u>1 hr</u>	<u>3 hr</u>	<u>5 hr</u>
25	Endotoxin 60 mg/kg	938	662	567
30	Endotoxin 60 mg/kg + T β_4 100 μ g administered simultaneously	807	591	496

TABLE XIII

<u>EXPERIMENTAL GROUPS</u>		<u>TNF-α (pg/ml) (serum level)</u>		
		<u>1 hr</u>	<u>3 hr</u>	<u>5 hr</u>
5	Endotoxin 60 mg/kg	938	662	567
	Endotoxin 60 mg/kg + T β_4 100 μ g administered immediately after endotoxin	807	591	496
10				

While the invention has been described and illustrated with details and references to certain preferred embodiments, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutes can be made without departing from the spirit of the invention.

Example 5

Using a septic shock model in rats (Sprague-Dawley, male, 200-225 g each), the effect of thymosin β_4 alone and together with antibiotics was studied. Peritonitis was induced in rats in the following way. A 1-cm incision was made into the peritoneal which exposed the cecum. A tight ligature was placed around the cecum with 4-0 suture distal to the insertion of the small bowel, forming an area of devitalized tissue while maintaining bowel continuity. A puncture wound was made with 16-gauge needle into the anti-mesenteric surface of the cecum and a small amount of fecal contents was expressed through the wound. The cecum was replaced into the peritoneal cavity, and the anterior peritoneal wall and skin were closed with

surgical staples. Each animal was given a bolus of normal saline (15 ml/kg) for hydration and allowed to recover overnight.

The results presented in Table XIX show $T\beta_4$ increased the survival of rats.

TABLE XIX

Survival of Sprague-Dawley rats following septic shock, antibiotics, and thymosin β_4

<u>EXPERIMENTAL GROUPS</u>	<u>0 hr</u>	<u>24 hr</u>	<u>48 hr</u>	<u>72 hr</u>
Rats with Septic Shock + antibiotic*	10	1	1	0
Rats with Septic Shock + antibiotic* + thymosin β_4 1 mg/rat x 3**	10	4	3	3

* gentamicin sulfate, 1 mg/rat

** At 0 hr, 2 hr, and 4 hr post induction of peritonitis

The results presented in Tables XX to XXIII below show effects of $T\beta_4$ respectively on rat cytokine levels, blood malonyldialdehyde levels, glutathione levels and arachidonic acid metabolic levels.

TABLE XX

The effect of $T\beta_4$ on Cytokine Levels in a septic shock model in rat

<u>EXPERIMENTAL GROUPS</u>	<u>TNFα (pg/ml)</u>	<u>ILα (pg/ml)</u>
Control	undetectable	undetectable
Rats with Septic Shock	2658 \pm 197	1387 \pm 123
Rats with Septic Shock + $T\beta_4$ 1 mg/rat x 3 as above	1259 \pm 138	853 \pm 62

SUBSTITUTE SHEET (RULE 26)

TABLE XXI

The effect of $T\beta_4$ on lipid peroxidation in
a septic shock model in rat

<u>EXPERIMENTAL GROUPS</u>	<u>Blood Levels of malonyldialdehyde (nMol MDA)</u>	
Control	15.3 \pm 1.3	18.6 \pm 1.1
Rats with Septic Shock	49.1 \pm 3.5	46.3 \pm 3.8
Rats with Septic Shock + $T\beta_4$ 1mg/rat x 3 as above	19.6 \pm 1.7	16.8 \pm 1.5

TABLE XXII

The effect of $T\beta_4$ on glutathione levels
in a rat septic shock model

<u>EXPERIMENTAL GROUPS</u>	<u>RBC GSH (μmoles/ml cells)</u>	
Control	1.38 \pm 0.1	1.46 \pm 0.13
Rats with Septic Shock	0.43 \pm 0.05	0.29 \pm 0.04
Rats with Septic Shock + $T\beta_4$ mg/rat x 3 as above	1.45 \pm 0.11	1.39 \pm 0.12

TABLE XXIII

The effect of $T\beta_4$ on arachidonic acid metabolite
levels in a septic shock model in rat

<u>EXPERIMENTAL GROUPS</u>	<u>6-keto-PGF₁ (pg/ml)</u>	<u>T x β_4 (pg/ml)</u>
Control	58 \pm 3.5	89 \pm 7.6
Rats with Septic Shock	1828 \pm 145.3	3622 \pm 295
Rats with Septic Shock + $T\beta_4$ 1 mg/rat x 3 as above	829 \pm 59	1627 \pm 123

The results presented in Tables XXIV and XXV below demonstrate that $T\beta_4$ increases the survival rate of rats with septic shock.

SUBSTITUTE SHEET (RULE 26)

TABLE XXIV

<u>EXPERIMENTAL GROUPS</u>	<u>Number of Rats Alive</u>			
	<u>0 h</u>	<u>24 h</u>	<u>48 h</u>	<u>72 h</u>
Rats with Septic Shock	10	2	2	0
Rats with Septic Shock + T β , 1 mg/rat x 3 as above	10	3	3	3

TABLE XXV

<u>EXPERIMENTAL GROUPS</u>	<u>Number of Rats Alive</u>			
	<u>0 h</u>	<u>24 h</u>	<u>48 h</u>	<u>72 h</u>
Rats with Septic Shock	10	1	0	0
Rats with Septic Shock + T β , 1 mg/rat x 3 as above	10	4	3	3

While the invention has been described and illustrated with details and references to certain preferred embodiments, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutes can be made without departing from the spirit of the invention.

What is claimed is:

1. A method of obstructing progression of a sepsis cascade in a mammal in which a sepsis cascade is occurring, comprising administering to said mammal a sepsis cascade progression-obstructing amount of thymosin β_4 ($T\beta_4$).

2. The method of claim 1, wherein said mammal is human.

3. The method of claim 2, wherein the $T\beta_4$ is administered at a dosage from about 0.4 to about 4 mg per kg of body weight of said mammal.

4. The method of claim 2, wherein the $T\beta_4$ is administered at a dosage from about 1 to about 4 mg per kg of body weight of said mammal.

5. The method of claim 3, wherein the $T\beta_4$ is administered parenterally.

6. The method of claim 5, wherein the $T\beta_4$ is administered intravenously.

7. The method of claim 1, wherein the $T\beta_4$ is synthetic $T\alpha_1$.

8. The method of claim 1, wherein said amount of $T\beta_4$ is sufficient to reduce in said mammal at least one member selected from the group consisting of cerebellar cGMP levels, blood malonyldialdehyde levels, blood glutathione levels, blood PAF levels, blood $Tx\beta_2$ levels, blood 6-keto-PGF $_{1\alpha}$ levels, blood IL-1 α levels and blood TNF α levels.

9. A method of preventing septic shock from occurring in a mammal following endotoxin introduction in said mammal, comprising administering to said mammal a septic shock-preventing effective amount of $T\beta_4$, wherein septic shock is prevented in said mammal for at least 72 hours after administration of said $T\beta_4$.

10. The method of claim 9 wherein septic shock is prevented in said mammal for at least 120 hours after administration of said $T\beta_4$.

11. The method of claim 9 wherein septic shock is prevented in said mammal for at least 14 days after administration of said $T\beta_4$.

12. The method of claim 9 wherein said mammal is human.

13. The method of claim 12, wherein the $T\beta_4$ is administered at a dosage from about 0.4 to about 4 mg per kg of body weight of said mammal.

14. The method of claim 12, wherein the $T\beta_4$ is administered at a dosage from about 1 to about 4 mg per kg of body weight of said mammal.

15. The method of claim 13, wherein the $T\beta_4$ is administered parenterally.

16. The method of claim 15, wherein the $T\beta_4$ is administered intravenously.

17. The method of claim 9, wherein the $T\beta_4$ is synthetic $T\beta_4$.

18. The method of claim 9, wherein said amount of $T\beta_4$ is sufficient to reduce in said mammal at least one member selected from the group consisting of cerebellar cGMP levels, blood malonyldialdehyde levels, blood glutathione levels, blood PAF levels, blood $Tx\beta_2$ levels, blood 6-keto-PGF $_{1\alpha}$ levels, blood IL-1 α levels and blood TNF α levels.

19. A method of treating septic shock in a mammal which comprises administering to said mammal a septic shock-treating effective amount of $T\beta_4$.

20. The method of claim 19, wherein said mammal is human.

SUBSTITUTE SHEET (RULE 26)

21. The method of claim 20, wherein the $T\beta_4$ is administered at a dosage from about 0.4 to about 4 mg per kg of body weight of said mammal.

22. The method of claim 20, wherein the $T\beta_4$ is administered at a dosage from about 1 to about 4 mg per kg of body weight of said mammal.

23. The method of claim 22, wherein the $T\beta_4$ is administered parenterally.

24. The method of claim 23, wherein the $T\beta_4$ is administered intravenously.

25. The method of claim 19, wherein the $T\beta_4$ is synthetic $T\beta_4$.

26. The method of claim 19, wherein said amount of $T\beta_4$ is sufficient to reduce in said mammal at least one member selected from the group consisting of cerebellar cGMP levels, blood malonyldialdehyde levels, blood glutathione levels, blood PAF levels, blood $Tx\beta_2$ levels, blood 6-keto-PGF $_{1\alpha}$ levels, blood IL-1 α levels and blood TNF α levels.

27. A pharmaceutical dosage unit containing an amount of $T\beta_4$ selected from the group consisting of a mammalian sepsis cascade progression-obstructing effective amount of $T\beta_4$, a mammalian septic shock-preventing effective amount of $T\beta_4$ and a mammalian septic shock-treating effective amount of $T\beta_4$, wherein said $T\beta_4$ is provided in a carrier which is pharmaceutically acceptable for administration to a mammal.

28. The pharmaceutical dosage unit of claim 27, containing from about 0.4 to about 4 mg $T\beta_4$ per kg of mammalian body weight.

29. The pharmaceutical dosage unit of claim 27, containing from about 1 to about 4 mg $T\beta_4$ per kg of mammalian body weight.

30. The pharmaceutical dosage unit of claim 28 which is in a form for parenteral administration, wherein the carrier is a sterile liquid carrier suitable for parenteral administration.

31. The pharmaceutical dosage unit of claim 30 which is in a form for intravenous administration.

32. The pharmaceutical dosage unit of claim 31, wherein the $T\beta_4$ is dissolved in a sterile isotonic saline solution.

33. The pharmaceutical dosage unit of claim 27, wherein said $T\beta_4$ is present in said pharmaceutical dosage unit in an amount sufficient to reduce in said mammal at least one member selected from the group consisting of cerebellar cGMP levels, blood malonyldialdehyde levels, blood glutathione levels, blood PAF levels, blood $Tx\beta_2$ levels, blood 6-keto-PGF $_{1\alpha}$ levels, blood IL-1 α levels and blood TNF α levels.

34. The method of claim 1, wherein said administration of $T\beta_4$ reduces blood free radical levels in said mammal.

35. The method of claim 9, wherein said administration of $T\beta_4$ reduces blood free radical levels in said mammal.

36. The method of claim 19, wherein said administration of $T\beta_4$ reduces blood free radical levels in said mammal.

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 94/10879A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CANCER IMMUNOLOGY IMMUNOTHERAPY, vol.14, no.3, March 1983, BERLIN pages 145 - 150 ISHITSUKA H. ET AL. 'Protective Activity of Thymosin Against Opportunistic Infections in Animal Models' see the whole document ---	1-36
A	US,A,4 297 276 (GOLDSTEIN A.L.) 27 October 1981 cited in the application see the whole document -----	1-36

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

6 January 1995

Date of mailing of the international search report

25.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 94/ 10879

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1 to 26 and 34 to 36 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Information on patent family members

PCT/US 94/10879

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)